Evidence supporting the use of: Immunoglobulin G
For the health condition: Enteritis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Immunoglobulin G (IgG) has been investigated as a therapeutic agent for enteritis, particularly in the form of orally administered serum-derived bovine immunoglobulin/protein isolate (SBI). Scientific validation exists primarily for its use in certain types of enteritis, such as enteropathy associated with HIV, inflammatory bowel disease (IBD), and irritable bowel syndrome with diarrhea (IBS-D). The proposed mechanism involves IgG binding to microbial antigens and toxins in the gut, neutralizing their effects, and reducing gut inflammation.

Several randomized controlled trials and open-label studies have shown that oral IgG can improve gastrointestinal symptoms, reduce stool frequency, and improve quality of life in patients with various forms of enteritis and enteropathy. For example, a double-blind, placebo-controlled trial published in Clinical and Translational Gastroenterology (2015) demonstrated significant symptom improvement in IBS-D patients receiving SBI. Additional studies in HIV-associated enteropathy have also reported clinical benefits.

However, the evidence base is moderate rather than robust. Most studies have small sample sizes, and there is limited long-term data. While IgG is not a first-line therapy for infectious enteritis, it may have a role in chronic or refractory cases where immune-mediated mechanisms are suspected. Major gastroenterology guidelines do not routinely recommend IgG therapy for general enteritis, but its use is considered reasonable in select scenarios based on the current scientific literature.

More about Immunoglobulin G
More about Enteritis

Products containing Immunoglobulin G

We currently have no products on Vitabase that contain this ingredient.